A 12-month placebo-controlled study using oral curcumin, Biocurcumax, 500mg three times a day was undertaken in cognitively healthy men and women (n=106), aged 65-90 years, at risk of Alzheimer's disease. Baseline peripheral blood biomarkers were also examined for their diagnostic value for determining levels of brain amyloid, using 18F-Florbetaben labelled positron emission tomography as a comparator. Elevated ferritin significantly correlated with high neocortical load, while fatty acid dysregulation, specifically elevated arachidonic acid and lower docosapentaenoic acid was also shown. No significant difference using curcumin was found between the intervention groups, in cognition or brain imaging.
|Qualification||Doctor of Philosophy|
|Award date||27 Feb 2022|
|Publication status||Unpublished - 2021|